---
title: 美国最高法院关闭了受欢迎的破产操作的门
date: 2024-06-28T04:00:28.070Z
description: Big companies that sought Chapter 11 to manage settlements will be forced to reconsider strategy after Purdue decision
tags: 
- us
author: ft
---

[原文链接](https://ft.com/content/d5feffa1-00f8-4e13-a7c4-965a63f9b3f7)

美国最高法院关闭了受欢迎的破产操作的门

# 摘要：
美国最高法院最近裁定禁止在破产程序中采用“非自愿第三方免责”的流行策略，这种策略允许公司通过第11章破产法院来管理和解并避免未来的诉讼。这一里程碑式的裁决使萨克尔家族（Sackler family）与珀杜制药公司（Purdue Pharma）相关的60亿美元和解协议无效，该协议涉及该公司2019年破产案件中的阿片类药物索赔。

最高法院裁定，根据现行法律，这些免责协议不受授权，应由国会处理。这一裁决对寻求通过破产法院的和解来保护自己免于未来责任的私募股权公司、工业首席执行官、制药制造商和其他公司产生了影响。

这一决定可能会导致重新评估强势参与者如何利用破产制度，并可能导致为未来的索赔人和持不同意见者提供较少的资金来解决大规模的侵权行为案件。然而，一些专家认为，这一裁决将有助于防止未经国会批准的破产法院中的优惠交易。

## 要点：
- 美国最高法院裁定禁止第11章破产案件中的“非自愿第三方免责”。
- 涉及萨克尔家族和珀杜制药公司的60亿美元和解协议被无效。
- 对寻求通过破产法院的和解来保护自己免于未来责任的私募股权公司、工业首席执行官、制药制造商等产生了影响。
- 这一裁决可能会导致重新评估强势参与者如何利用破产制度，并可能导致为未来的索赔人和持不同意见者提供较少的资金来解决大规模的侵权行为案件。
- 一些专家认为，这一裁决将有助于防止未经国会批准的破产法院中的优惠交易。

---

 **Summary:**  
The US Supreme Court recently ruled against popular bankruptcy manoeuvres involving "non-consensual third-party releases," which allowed companies to manage settlements and avoid future lawsuits through Chapter 1n bankruptcy court. The landmark ruling invalidated a $6bn settlement by the Sackler family, owners of Purdue Pharma, related to opioid claims in the company's 2019 bankruptcy case.

The Supreme Court found that these releases were not authorized under current law and should be addressed by Congress instead. The ruling has implications for private equity firms, industrial CEOs, pharmaceutical manufacturers, and other companies seeking to protect themselves from future liability through bankruptcy court settlements.

The decision may lead to a reevaluation of how powerful actors use the bankruptcy system and could result in less money being offered for mass tort resolution cases with future claimants and holdouts. However, some experts believe that this ruling will help prevent sweetheart deals in bankruptcy court not sanctioned by Congress.

**Key Points:**  
- US Supreme Court rules against "non-consensual third-party releases" in Chapter 1n bankruptcy cases.
- $6bn settlement involving the Sackler family and Purdue Pharma invalidated.
- Implications for private equity firms, industrial CEOs, pharmaceutical manufacturers, etc., seeking to protect themselves from future liability through bankruptcy court settlements.
- Ruling may lead to reevaluation of how powerful actors use the bankruptcy system and could result in less money being offered for mass tort resolution cases with future claimants and holdouts.
- Some experts believe that this ruling will help prevent sweetheart deals in bankruptcy court not sanctioned by Congress.

[Source Link](https://ft.com/content/d5feffa1-00f8-4e13-a7c4-965a63f9b3f7)

